The U.S. Food and Drug Administration on Sept. 21 approved Incyte Corp.’s cream Opzelura for treating the inflammatory skin condition atopic dermatitis, commonly called eczema, in adolescents and adults with boxed warnings.
Dermavant Sciences announced positive data from two Phase III clinical trials evaluating tapinarof cream 1% in adults with plaque psoriasis.
The U.S. Food and Drug Administration approved Italy-based Cassiopea SpA’s acne treatment Winlevi (clascoterone cream 1%).
The U.S. Food and Drug Administration approved MC2 Therapeutics’ Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) for once-daily topical treatment of plaque psoriasis in adults 18 years of age or older.
